Clinical trial · Interventional
Homeopathic Protocol for Advanced Breast Cancer
The Banerji Protocol for Advanced Breast Cancer- Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Not able to recruit patients
Summary
Brief summary (as posted)
The objective of this study is to conduct a feasibility study at Meir Oncology Institute examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months. The primary aim of the study is to establish if patients with advanced breast cancer in Meir Oncology Institute would follow a regimen of treatment as used by Dr Banerji in India, for six months. The secondary aim is to observe the quality of life and wellbeing of patients undergoing this protocol
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Homeopathic treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Homeopathic treatment
- description
- A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
- interventionNames
- Other: Homeopathic treatment
Primary outcomes (1)
- measure
- To establish if patients with advanced breast cancer in Meir Oncology Institute would follow a homeopathic treatment protocol as used by Dr Banerji in India, for six months.
- timeFrame
- Six months
- description
- Investigators will follow patients with advanced breast cancer in Meir Oncology Institute and see if patients would follow a homeopathic treatment protocol as used by Dr Banerji in India, for six months.
Secondary outcomes (1)
- measure
- Observe and verify the quality of life and wellbeing of patients undergoing this protocol
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Ability to speak and read Hebrew/English with patients residing in Israel. * Diagnosis of advanced breast cancer treated and followed in Meir Oncology Institute * Patients that cannot participate in conventional cancer care due to side effects, expected adverse reactions or other reasons that prevent them from utilizing conventional care. * Patients, who for their own reasons elect to refuse conventional treatment, can be offered to participate in the study in order to keep them in the system and not lose them to alternative untested treatments. * Consent to participate in this study Exclusion Criteria: * Inability to understand the intent of the study and follow the instructions * Medical condition that would preclude participation in an interview session lasting 15-30 minutes * Diagnosis of active psychosis or severe cognitive impairment confirmed by the patient's attending physician.
References
Publications (1)
- RESULTFrenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P, Banerji P. Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol. 2010 Feb;36(2):395-403. PMID 20043074